|
|
|
Insider
Information: |
Kauffman Michael |
Relationship: |
Director |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
800,347 |
|
Indirect Shares
|
898,131 |
|
|
Direct
Value |
$971,028 |
|
|
Indirect Value
|
$1,032,851 |
|
|
Total
Shares |
1,698,478 |
|
|
Total
Value |
$2,003,879 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
12
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
12
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-12.0
|
Percentage
Gain/Loss : |
0.0%
|
-553.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Onyx Pharmaceuticals Inc |
ONXX |
Chief Medical Officer |
2010-02-09 |
9,000 |
2009-11-16 |
0 |
Premium* |
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-02-28 |
713,757 |
2022-02-28 |
898,131 |
Premium* |
|
Verastem, Inc. |
VSTM |
Director |
2018-09-28 |
8,000 |
2014-09-17 |
0 |
Premium* |
|
Kezar Life Sciences, Inc. |
KZR |
Director |
2022-01-03 |
63,690 |
2018-06-25 |
0 |
Premium* |
|
Adicet Bio, Inc |
ACET |
Director |
2023-06-01 |
5,900 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
156 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-07-18 |
4 |
OE |
$0.03 |
$21,678 |
D/D |
10,000 |
522,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-07-18 |
4 |
AS |
$18.27 |
$182,686 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-08-07 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
726,010 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-08-07 |
4 |
AS |
$18.04 |
$225,556 |
I/I |
(12,500) |
713,510 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-08-20 |
4 |
AS |
$17.46 |
$174,568 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-08-20 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
522,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-09-07 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
726,010 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-09-07 |
4 |
AS |
$19.31 |
$241,384 |
I/I |
(12,500) |
713,510 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-09-18 |
4 |
AS |
$18.26 |
$182,615 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-09-18 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
522,143 |
0 |
- |
|
VSTM |
Verastem, Inc. |
Director |
|
2018-09-28 |
4 |
B |
$7.49 |
$29,960 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
VSTM |
Verastem, Inc. |
Director |
|
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
8,000 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-10-08 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
726,010 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-10-08 |
4 |
AS |
$15.39 |
$196,832 |
I/I |
(12,500) |
713,510 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-10-18 |
4 |
AS |
$12.63 |
$126,304 |
D/D |
(10,000) |
512,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-10-18 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
522,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-11-07 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
726,010 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-11-07 |
4 |
AS |
$11.65 |
$145,593 |
I/I |
(12,500) |
713,510 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-11-19 |
4 |
AS |
$11.14 |
$4,455 |
D/D |
(400) |
512,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-11-19 |
4 |
OE |
$4.75 |
$1,901 |
D/D |
400 |
512,543 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-11-26 |
4 |
OE |
$4.75 |
$45,619 |
D/D |
9,600 |
521,743 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-11-26 |
4 |
AS |
$11.00 |
$105,600 |
D/D |
(9,600) |
512,143 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-12-07 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
726,010 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2018-12-07 |
4 |
AS |
$10.11 |
$126,423 |
I/I |
(12,500) |
713,510 |
0 |
- |
|
KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
|
2019-01-07 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
743,634 |
0 |
- |
|
156 Records found
|
|
Page 3 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|